The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia

Urology

Volumn 47, Issue 2, 1996, Pages 159-168

  Roehrborn, Claus G ^a   Oesterling, Joseph E ^b   Auerbach, Stephen ^b   Kaplan, Stephen A ^b   Lloyd, L Keith ^b   Milam, Douglas F ^b   Padley, Robert J ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; TERAZOSIN;

ADULT; AGED; ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY EXCRETION; UROFLOWMETRY; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE; UNITED STATES; URODYNAMICS;

EID: 0029939081     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80409-9     Document Type: Article

References (31)

1. Roberts RO, Rhodes T, Panser LA, Girman CJ, Chute CG, Oesterling JE, Lieber MM, and Jacobsen SJ: Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology 43: 621-628, 1994.
2. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, and Proctor C: Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 141: 248-253, 1989.
3. Lepor H: Nonoperative management of benign prostatic hyperplasia. J Urol 141: 1283-1289, 1989.
4. Lepor H: Alpha adrenergic antagonists for the treatment of symptomatic BPH. Int J Clin Pharmacol 27: 151-155, 1989.
5. Gup DI, Shapiro E, Baumann M, and Lepor H: Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 15: 105-114, 1989.
6. Caine M, Pfau A, and Perlberg S: The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48: 255-263, 1976.
7. Lepor H, Knapp-Maloney G, and Wozniak-Petrofsky J: The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. Int J Clin Pharmacol 27: 392-397, 1989.
8. Lepor H, and Laddu A: Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. Br J Urol 70 (suppl 1): 2-9, 1992.
9. Lepor H, Meretyk S, and Knapp-Maloney G: The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. J Urol 147: 1554-1557, 1992.
10. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, and Madsen P: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474, 1992.
11. Christensen MM, Bendix Holme J, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP, Olesen S, Noer I, Wolf H, and Husted SE: Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol 27: 39-44, 1993.
12. Jardin A, Bensadoun H, Delauche-Cavallier MC, and Attali P: Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 337: 1457-1461, 1991.
13. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ, and Abrams P: A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74: 50-56, 1994.
14. McConnell JD, Barry MJ, and Bruskewitz RC: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Agency for Health Care Policy and Research. Clinical Practice Guideline 8: 1-17, 1994.
15. Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 45: 406-413, 1995.
16. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, and Cockett ATL: The American Urological Association's symptom index for benign prostatic hyperplasia. J Urol 148: 1549-1557, 1992.
17. O'Leary MP, Barry MJ, and Fowler FJ Jr: Hard measures of subjective outcomes: validating symptom indexes in urology. J Urol 148: 1546-1548, 1992.
18. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, and Mebust WK: Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 33: AS145-155, 1995.
19. Hillman AL, Schwartz JS, Willian MK, Peskin E, Roehrborn CG, Oesterling JE, Mason MF, Maurath C, Deverka PA, and Padley RJ: The cost-effectiveness of terazosin and placebo in the treatment of moderate-to-severe benign prostatic hyperplasia. Urology 47: 169-178, 1996.
20. Fowler FJ Jr, Wennberg JE, Timothy RP, Barry MJ, Mulley AG Jr, and Hanley D: Symptom status and quality of life following prostatectomy. JAMA 259: 3018-3022, 1988.
21. Barry MJ, Mulley AG Jr, Fowler FJ, and Wennberg JW: Watchful waiting vs immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences. JAMA 259: 3010-3017, 1988.
22. Barry MJ: Medical outcomes research and benign prostatic hyperplasia. Prostate 3 (suppl): 61-74, 1990.
23. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE, and Lieber MM: Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 44: 825-831, 1994.
24. Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, and Murphy G: The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Proceedings, Jersey, Channel Islands, Scientific Communication International Ltd, 1993.
25. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327: 1185-1191, 1992.
26. Brawer MK, Adams G, and Epstein H: Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 2: 929-935, 1993.
27. Barry MJ, Williford WO, Chang YC, Machi M, Jones KM, Walker-Corkery W, and Lepor H: BPH-specific health status measures in clinical research: how much change in AUA Symptom Index and the BPH Impact Index is perceptible to patients? J Urol 154: 1770-1774, 1995.
28. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, and Winfield HN: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 150: 351-358, 1993.
29. Christensen MM, Bendix Holme J, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP, Olesen S, Noer I, Wolf H, and Husted SE: Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol 27: 39-44, 1993.
30. Lepor H, Henry D, and Laddu AR: The efficacy and safety of terazosin for the treatment of symptomatic BPH. Prostate 18: 345-355, 1991.
31. Khoury AF, and Kaplan NM: Alpha-blocker therapy of hypertension. An unfulfilled promise. JAMA 266: 394-398, 1991.